Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Optimer Pharmaceuticals
So what: The company's experimental antibiotic, fidaxomicin, passed a key test when the FDA agreed with the company's efficacy claims. The drug, which fights life-threatening diarrhea, is headed to an advisory panel Tuesday.
Now what: There are still concerns about safety, as 25.7% of fidaxomicin patients had serious complications, but the market is overlooking that risk. Analysts expect $203 million in sales annually if the drug gets final approval. Good news from the advisory panel could spark another move for the stock. Stay tuned.
Interested in more info on Optimer Pharmaceuticals? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.